Ms. Michelle Lefler reports
AURORA CANNABIS CLOSES PREVIOUSLY ANNOUNCED BOUGHT DEAL FINANCING
Aurora Cannabis Inc. has closed its previously announced bought deal public offering of units of the company for total gross proceeds of $137.94-million (U.S.). The company sold 13.2 million units at a price of $10.45 (U.S.) per unit, including 1.2 million units sold pursuant to the exercise in full of the underwriters' overallotment option.
Each unit comprised one common share of the company and one-half of one common share purchase warrant of the company. Each warrant is exercisable to acquire one common share of the company for a period of 36 months following the closing date of the offering at an exercise price of $12.60 (U.S.) per warrant share, subject to adjustment in certain events.
BMO Capital Markets and ATB Capital Markets acted as the bookrunners for the offering.
The company plans to use the net proceeds of the offering for general corporate purposes, which may include opportunistically reducing debt. The company believes that the offering fits with its broader strategy to have a strong balance sheet while maintaining maximum flexibility to invest and build toward being a leader in global cannabinoids.
In connection with the offering, the company filed a prospectus supplement to the company's short-form base-shelf prospectus dated Oct. 28, 2020, with the securities commissions or similar securities regulatory authorities in each of the provinces of Canada, except Quebec, and with the U.S. Securities and Exchange Commission as part of the company's registration statement on Form F-10 under the United States/Canada multijurisdictional disclosure system. The prospectus supplement, the base-shelf prospectus and the registration statement contain important detailed information about the company and the offering.
Copies of the prospectus supplement and the base-shelf prospectus are available on SEDAR, and copies of the prospectus supplement and the registration statement are available on EDGAR. Copies of the prospectus supplement, the base-shelf prospectus and the registration statement may also be obtained from BMO Capital Markets by contacting BMO Capital Markets, Brampton Distribution Centre c/o The Data Group of Companies, 9195 Torbram Rd., Brampton, Ont., L6S 6H2, or by telephone at 905-791-3151 extension 431, or by e-mail at firstname.lastname@example.org, or from BMO Capital Markets Corp., attention: Equity Syndicate Department, 3 Times Square, 25th floor, New York, N.Y., 10036 (attention: Equity Syndicate), or by telephone at 800-414-3627 or by e-mail at email@example.com. Copies of such documents may also be obtained from ATB Capital Markets Inc., attention: Gail O'Connor, 410-585 8th Ave. SW, Calgary, Alta., T2P 1G1, 403-539-8629, or by e-mail from firstname.lastname@example.org.
Aurora is a global leader in the cannabis industry, serving both the medical and consumer markets. Headquartered in Edmonton, Alta., Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The company's brand portfolio includes Aurora, Aurora Drift, San Rafael '71, Daily Special, AltaVie, MedReleaf, CanniMed, Whistler and Reliva CBD. Providing customers with innovative, high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, performance, wellness and recreational markets wherever they are launched.
We seek Safe Harbor.
© 2021 Canjex Publishing Ltd. All rights reserved.